
‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More










